Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

French study tracks Real-World CLL care to improve patient outcomes

NCT ID NCT05590702

Knowledge-focused Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 1,000 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in France to see how they are actually treated in everyday clinics, not just in controlled trials. Researchers will track which therapies patients receive, in what order, and how that affects their long-term survival and side effects. The goal is to learn from real-world experience to guide better treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18-year old * CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation * Patient requiring therapy for immune events (autoimmune Thrombocytopenia and autoimmune hemolytic anemia) are eligible * Patients who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control * All consecutive patients for whom a discussion in the setting of local or regional multidisciplinary collegial meeting (in french : réunion de concertation pluridisciplinaire / RCP) has retained the need for starting a therapeutic strategy (curative or palliative) * Patients with untreated or previously treated CLL/SLL are both eligible * Patients enrolled in a clinical trial can be included in this non-interventional cohort study * Patients requiring therapy for CLL/SLL-associated immune events only are also eligible Exclusion Criteria: * Patients with no need of therapy * Patients with asymptomatic Binet A CLL * Patient with Richter's syndrome at inclusion * Patient requiring immunoglobulin substitution (with no need of a more specific therapy)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLL/SLL

Contacts and locations

Locations

  • AMIENS - CH Amiens Picardie Site Sud

    Amiens, 80054, France

  • ANNECY - CH Annecy Genevois

    Annecy, 74374, France

  • APHP - HOPITAL COCHIN - Hématologie

    Paris, 75014, France

  • APHP - Hôpital Avicenne

    Bobigny, France

  • APHP - Hôpital Jean Verdier

    Bondy, 93140, France

  • APHP - Hôpital Pitié Salpêtrière - Hématologie

    Paris, 75651, France

  • ARGENTEUIL - Centre hospitalier Victor Dupouy

    Argenteuil, France

  • AVIGNON - Centre Hospitalier

    Avignon, 84000, France

  • Angers Chu

    Angers, 49933, France

  • BESANCON - Hôpital Jean Minjoz

    Besançon, 25000, France

  • BEZIERS - Centre Hospitalier - Hématologie

    Béziers, 34500, France

  • BLOIS CH

    Blois, 41000, France

  • BOURGOUIN-JALLIEU - CH Pierre Oudot

    Bourgoin, 38300, France

  • BREST - Hôpital Morvan - Hématologie Clinique

    Brest, 29609, France

  • Bordeaux Pessac

    Pessac, 33604, France

  • CAEN - IHBN - Hématologie Clinique

    Caen, 14033, France

  • CERGY PONTOISE - CH René Dubos

    Cergy-Pontoise, France

  • CHAMBERY - CH Métropole Savoie

    Chambéry, 73000, France

  • Clermont-Ferrand - Chu Estaing

    Clermont-Ferrand, 63000, France

  • Corbeil-Essonnes - Chsf

    Corbeil-Essonnes, France

  • Dijon Chu

    Dijon, 21000, France

  • GRENOBLE GHM - Institut Daniel Hollard

    Grenoble, 38028, France

  • Grenoble - CHUGA - Hématologie Clinique

    Grenoble, 38043, France

  • LENS - GHT Artois

    Lens, 62300, France

  • LIBOURNE - Hôpital Robert Boulin

    Libourne, 33505, France

  • LILLE CHU - Hôpital Claude Huriez

    Lille, 59037, France

  • LILLE GHICL - Hôpital Saint Vincent de Paul

    Lille, 59000, France

  • LIMOGES - CHU Dupuytren 1

    Limoges, 87042, France

  • LYON HCL - CH Lyon Sud

    Pierre-Bénite, 69036, France

  • LYON-Centre Léon Bérard

    Lyon, 69008, France

  • La Reunion - Gh Site Sud

    Saint-Pierre, France

  • La Roche Sur Yon - Chd Vendee

    La Roche-sur-Yon, 85925, France

  • Le Mans CH

    Le Mans, France

  • METZ-THIONVILLE CHR- Hôpital de Mercy

    Metz, France

  • MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique

    Montpellier, 34295, France

  • MORLAIX - CH des pays de Morlaix

    Morlaix, 29672, France

  • Mulhouse - Ghrmsa

    Mulhouse, 68100, France

  • NANCY - CHU Brabois

    Vandœuvre-lès-Nancy, 54500, France

  • NANTES - Hôpital Hôtel Dieu - Hématologie Clinique

    Nantes, 44093, France

  • NIMES - CHU Caremeau

    Nîmes, 30029, France

  • ORLEANS - CHR - Hématologie

    Orléans, 44100, France

  • PERPIGNAN - CH St Jean - Hématologie Clinique

    Perpignan, 66000, France

  • Perigueux - Ch

    Périgueux, 24000, France

  • QUIMPER - CH de Cornouaille

    Quimper, 29000, France

  • RENNES - CHU Pontchaillou - Hématologie Clinique

    Rennes, 35033, France

  • RENNES - Hôpital Pontchaillou - Hématologie

    Rennes, 35033, France

  • ROUEN - Centre Henri Becquerel - Service Hématologie Clinique

    Rouen, 76038, France

  • Reims Chu

    Reims, 51092, France

  • SAINT-BRIEUC - Hôpila Yves Le Foll

    Saint-Brieuc, 22027, France

  • ST ETIENNE - CHU et Institut De Cancérologie Lucien Neuwirth

    Saint-Priest-en-Jarez, France

  • Strasbourg - Icans

    Strasbourg, 67033, France

  • TOURS - Hôpital Bretonneau

    Tours, 37000, France

  • Toulouse - IUCT Oncopole - Service d'Hématologie

    Toulouse, 31059, France

  • Troyes Ch

    Troyes, France

  • VERSAILLES - Hôpital André Mignot

    Versailles, France

  • Vannes - Chba

    Vannes, France

  • Villejuif Igr

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.